Efficacy and safety of combined cyclosporin A and mycophenolate mofetil therapy in patients with cyclosporin-resistant focal segmental glomerulosclerosis;Eficacia y seguridad del tratamiento combinado con ciclosporina A y micofenolato de mofetilo en enfermos con glomeruloesclerosis segmentaria y focal ciclosporina-resistente

Nefrologia

Volumn 31, Issue 3, 2011, Pages 286-291

  Medrano, A Segarra ^a   Presas, J Vila ^a   Clavé, L Pou ^a   Masferrer, J Majó ^a   Domenech, J Camps ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cyclosporin A; Cyclosporine resistance; Focal and segmental glomeruloesclerosis; Mycophenolate mofetil

Indexed keywords

CYCLOSPORIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTICLE; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; MALE; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY;

CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 79958265995     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2011.Feb.10870     Document Type: Article

References (20)

1. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993;43:1377-84.
2. Lee HY, Kim HS, Kang CM, Kim SG, Kim MJ. The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: A multicenter study in Korea. Clin Nephrol 1995;43:375-81.
3. Meyrier A, Noel LH, Auriche P, Callard P, and the Collaborative Group of the Société de Néphrologie. Long-term term renal tolerance of cyclosporine A treatment in adult idiopathic nephrotic syndrome. Kidney Int 1994;45:1446-56.
4. Cattran DC, Appel GB, Herbert LA, Hunsicker LG, et al, for the North America Nephrotic Syndrome Study Group. A randomized trial of cyclosporine in patients with steroid-resistant focal glomerulosclerosis. Kidney Int 1999;56:2220-6.
5. Briggs WA, Choi MJ, Scheel PJ. Follow-up on mycophenolate treatment of glomerular disease. Am J Kidney Dis 1998;31:898-9.
6. Radhakrishnan J, Wang MM, Matalon A, Cattran DC, Appel GB. Mycophenolate mofetil treatment of idiopathic focal segmental glomerulosclerosis [Abstract]. J Am Soc Nephrol 1999;114A:A584.
7. Segarra A, Amoedo ML, Martínez García JM, Pons S, Praga M, et al. Efficacy and safety of «rescue therapy» with mycophenolate mofetil in resistant primary glomerulonephritis-a multicenter study. Nephrol Dial Transplant 2007;22(5):1351-60.
8. Choi, MJ, Eustace, JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002;61:1098-114.
9. Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 2002;17:2011-3.
10. Levin ML. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002;62:1475.
11. Bullo B, Zdrojewski Z, Rutkowski B. Mycophenolate mofetil (MMF) therapeutic approach in patients with chronic glomerulonephritis (GN). Kidney Int 2003;64:1139.
12. Dimitrakov DJ, Nikolov DG, Dimitrakov JD, Despotov TB, et al. Effect of mycophenolate mofetil (Cell Cept) in the treatment of immune glomerulopathies. Folia Med (Plovdiv) 2004;46:15-8.
13. Cattran DC, Wang MM, Appel G, Matalon A, Briggs W. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004;62(6):405-11.
14. Ostraat O, Qi Z, Olausson M, Gannedahl G, Tufveson G, Ekberg H. Additive immunosuppressive effect of combined mycophenolate mofetil and cyclosporine A in experimental rat cardiac transplantation. Transplant Proc 1995;27(6):3540.
15. Ostraat O, Qi Z, Olausson M, Tufveson G, Ekberg H. Mycophenolate mofetil, azathioprine and cyclophosphamide enhanced efficacy combined with cyclosporine in rat cardiac transplantation. Scand J Immunol 1997;45(4):343-8.
16. El-Reshaid K, El-Reshaid W, Madda J. Combination of immunosuppressive agents in treatment of steroid-resistant minimal change disease and primary focal segmental glomerulosclerosis. Ren Fail 2005;27(5):523-30.
17. Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 1995;25(4):534-42.
18. Ponticelli C, Villa M, Banfi G, et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis 1999;34:618-25.
19. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal Segmental Glomerulosclerosis in Nephrotic Adults: Presentation, Prognosis, and Response to Therapy of the Histological Variants. J Am Soc Nephrol 2004;15:2169-77.
20. Troyanov S, Wall CA, Miller JA, et al. Focal and segmental glomerulosclerosis: Definition and relevance of a partial remission. J Am Soc Nephrol 2005;16(4):1061-8.